Crossmark

Circulating PCSK9 relates to aggravated disease activity, Th17/Treg imbalance, and predicts treatment outcome of conventional synthetic DMARDs in rheumatoid arthritis patients

Crossref DOI link: https://doi.org/10.1007/s11845-023-03323-8

Published Online: 2023-02-24

Published Print: 2023-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Meng, Yanan

Zheng, Xiaomeng

Zhang, Zheng

Geng, Huijuan

Li, Xiaodong
License Information

Text and Data Mining valid from 2023-02-24

Version of Record valid from 2023-02-24
More Information

Article History

Received: 19 October 2022

Accepted: 17 February 2023

First Online: 24 February 2023

Declarations

:

: The Ethics Committee has approved this research. All patients and healthy individuals provided written informed consent.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below